Appendix Table A1.

Baseline Differences Between the Control (Nonparticipant) and Intervention (Participant) Groups

Members' demographic and clinical attributes	Control group (%)	Intervention group (%)	p
Age (in years)	85.1	86.5	<0.0337
65–74	5.4	2.8	<0.1598
75–84	30.9	25.0	<0.1350
85–99	63.2	72.2	<0.0283
Male	54.2	54.6	<0.9380
Female	45.3	45.5	<0.9643
Program length of stay (in days)	272	184	<0.0000
AMI	4.2	2.3	<0.2371
Alzheimer's disease and related disorders or senile dementia	21.4	11.9	<0.0053
Atrial fibrillation	47.7	49.4	<0.6910
CKD	54.2	46.0	<0.0573
Chronic obstructive pulmonary disease and bronchiectasis	43.7	39.8	<0.3592
Depression	23.3	19.9	<0.3386
Diabetes type 1	5.6	6.8	<0.5534
Diabetes type 2	34.0	33.0	<0.7911
HF	46.3	43.2	<0.4656
Hip/pelvic fracture	3.9	2.3	<0.3157
IHD	50.5	42.1	<0.0491
RA/OA	38.3	40.9	<0.5263
Stroke/transient ischemic attack	12.6	10.8	<0.5153
Female/male breast cancer	4.56	2.8	<0.3174
Colorectal cancer	5.1	5.1	<0.9891
Prostate cancer	7.5	7.4	<0.9447
Lung cancer	9.8	8.5	<0.6069

AMI, acute myocardial infarction; CKD, chronic kidney disease; HF, heart failure; IHD, ischemic heart disease; RA/OA, rheumatoid arthritis/osteoarthritis.